JP2019501194A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501194A5
JP2019501194A5 JP2018535324A JP2018535324A JP2019501194A5 JP 2019501194 A5 JP2019501194 A5 JP 2019501194A5 JP 2018535324 A JP2018535324 A JP 2018535324A JP 2018535324 A JP2018535324 A JP 2018535324A JP 2019501194 A5 JP2019501194 A5 JP 2019501194A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
opioid
antagonist
opioid antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535324A
Other languages
English (en)
Japanese (ja)
Other versions
JP7061568B2 (ja
JP2019501194A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012452 external-priority patent/WO2017120417A1/en
Publication of JP2019501194A publication Critical patent/JP2019501194A/ja
Publication of JP2019501194A5 publication Critical patent/JP2019501194A5/ja
Application granted granted Critical
Publication of JP7061568B2 publication Critical patent/JP7061568B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535324A 2016-01-08 2017-01-06 オピオイド新生児薬物離脱症候群の処置及び予防 Active JP7061568B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276691P 2016-01-08 2016-01-08
US62/276,691 2016-01-08
PCT/US2017/012452 WO2017120417A1 (en) 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome

Publications (3)

Publication Number Publication Date
JP2019501194A JP2019501194A (ja) 2019-01-17
JP2019501194A5 true JP2019501194A5 (enExample) 2020-01-23
JP7061568B2 JP7061568B2 (ja) 2022-04-28

Family

ID=59274434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535324A Active JP7061568B2 (ja) 2016-01-08 2017-01-06 オピオイド新生児薬物離脱症候群の処置及び予防

Country Status (7)

Country Link
US (3) US10925870B2 (enExample)
EP (1) EP3400066B1 (enExample)
JP (1) JP7061568B2 (enExample)
CN (1) CN108778423A (enExample)
AU (1) AU2017206041B2 (enExample)
DK (1) DK3400066T3 (enExample)
WO (1) WO2017120417A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066284A1 (en) * 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
EP3883571B1 (en) * 2019-01-04 2026-01-28 Aether Therapeutics Inc. 6-beta-naltrexol for use in a method of treating opioid dependency
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US20240325379A1 (en) * 2021-07-06 2024-10-03 Aether Therapeutics Inc. Low-dose naltrexol and uses thereof
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4743601A (en) * 2000-03-15 2001-09-24 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
DE602004009449T2 (de) * 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug
EP1817023A4 (en) * 2004-11-16 2010-08-18 Limerick Biopharma Inc METHODS AND COMPOSITIONS FOR TREATING PAIN
CA2702680A1 (en) 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
WO2010065930A1 (en) * 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms

Similar Documents

Publication Publication Date Title
Labianca et al. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain
JP2009525343A5 (enExample)
JP2017510607A5 (enExample)
Sturn et al. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients
JP2016505050A5 (enExample)
JP2016520114A5 (enExample)
CR20240015A (es) COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
Patel et al. Opioids for pain after oral surgery
EP2830605A1 (en) A combination medicament comprising phenylephrine and paracetamol
JP6797691B2 (ja) ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途
KR101978459B1 (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
JP6940265B2 (ja) 止瀉剤組成物
Linn et al. Peripherally restricted μ-opioid receptor antagonists: a review
JP6940264B2 (ja) 止瀉剤組成物
KR101598283B1 (ko) 안전성 및 효능이 증가된 월경통 완화 또는 치료용 복합제 조성물
NZ744112B2 (en) Treatments and prevention of opioid neonatal abstinence syndrome
CN109966291A (zh) 化合物sb216763在制备预防和/或治疗脑血管疾病的药物中的应用及其药物组合物
NZ744112A (en) Treatments and prevention of opioid neonatal abstinence syndrome
CN103316346B (zh) 治疗癫痫的药物组合物
JP6753661B2 (ja) 止瀉剤組成物
Hellwig et al. The Role of Methylnaltrexone in Opioid-induced Constipation.
JP6676326B2 (ja) 止瀉用の漢方製剤
Chiou et al. The use of transdermal fentanyl in cancer pain—a compliance study of outpatients in Taiwan
Jerome Check et al. COMPLETE RESOLUTION OF THE BURNING MOUTH SYNDROME IN A NORMAL ESTROGENIC WOMAN FOLLOWING TREATMENT WITH AMPHETAMINES
Tran Altered mental status following postoperative toxicity: case report